Tirzepatide in community settings

From 23 June, some people living with obesity may be eligible to access tirzepatide (Mounjaro®) for weight loss purposes in community settings as outlined in NICE guidelines. Access is prioritised for those with the greatest clinical need (see page 7 of the interim commissioning guidance for eligibility criteria).

Initially, only a small number of people are eligible, including those people living with obesity, in poor health with multiple obesity related conditions, as they are likely to benefit most from the treatment.

Access routes and services will differ across each ICB. Clinicians will need to await details from their ICB on the weight management pathway in the community. This will include pathways for prescribing as well as referring into a ‘wraparound’ offer.

A communications toolkit is available to support with communicating about how tirzepatide will be implemented locally.